- Home
- BNY vs HRTX Comparison
BNY vs HRTX Comparison
Compare BNY & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- HRTX
- Stock Information
- Founded
- BNY 2001
- HRTX 1983
- Country
- BNY United States
- HRTX United States
- Employees
- BNY N/A
- HRTX N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- BNY Finance
- HRTX Health Care
- Exchange
- BNY Nasdaq
- HRTX Nasdaq
- Market Cap
- BNY 230.8M
- HRTX 206.9M
- IPO Year
- BNY N/A
- HRTX 1987
- Fundamental
- Price
- BNY $10.14
- HRTX $1.24
- Analyst Decision
- BNY
- HRTX Strong Buy
- Analyst Count
- BNY 0
- HRTX 2
- Target Price
- BNY N/A
- HRTX $4.50
- AVG Volume (30 Days)
- BNY 52.7K
- HRTX 1.4M
- Earning Date
- BNY 01-01-0001
- HRTX 11-11-2025
- Dividend Yield
- BNY 3.93%
- HRTX N/A
- EPS Growth
- BNY N/A
- HRTX N/A
- EPS
- BNY N/A
- HRTX N/A
- Revenue
- BNY N/A
- HRTX $149,694,000.00
- Revenue This Year
- BNY N/A
- HRTX $10.62
- Revenue Next Year
- BNY N/A
- HRTX $12.99
- P/E Ratio
- BNY N/A
- HRTX N/A
- Revenue Growth
- BNY N/A
- HRTX 9.78
- 52 Week Low
- BNY $8.60
- HRTX $1.04
- 52 Week High
- BNY $10.80
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- BNY 80.95
- HRTX 30.45
- Support Level
- BNY $9.39
- HRTX $1.25
- Resistance Level
- BNY $10.24
- HRTX $1.35
- Average True Range (ATR)
- BNY 0.08
- HRTX 0.06
- MACD
- BNY 0.06
- HRTX 0.01
- Stochastic Oscillator
- BNY 86.49
- HRTX 5.00
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.